Table 4.
Sensitivity analyses estimating changes in total annual cost (in millions) of four major adult vaccine-preventable diseases in 2013 based on hypothetical epidemiological scenarios, 2013 US dollars
| Adults aged 50 and older | Adults aged 65 and older | |||
|---|---|---|---|---|
| Total cost (millions) |
$ Changea
(millions) |
Total cost (millions) |
$ Changea
(millions) |
|
| Base case | $26,513.8 | n.a. | $15,329.9 | n.a. |
| % Of US population that develops influenza annually | ||||
| 5 | $20,993.9 | −$5519.9 | $11,659.4 | −$3670.5 |
| 20 | $50,110.5 | $23,596.7 | $25,423.7 | $10,093.8 |
| 25 | $62,972.9 | $36,459.1 | $30,011.9 | $14,682.0 |
| 40 | $94,457.3 | $67,943.5 | $43,754.6 | $28,424.7 |
| % Of patients who develop pneumonia who are hospitalized | ||||
| 30 | $25,876.8 | −$637.0 | $14,473.2 | −$856.7 |
| 50 | $27,684.7 | $1170.9 | $15,791.7 | $461.8 |
| 60 | $28,590.5 | $2076.7 | $16,450.9 | $1121.0 |
| % Of herpes zoster patients who develop PHN | ||||
| 10 | $26,106.2 | −$407.6 | $15,044.5 | −$285.4 |
| 20 | $26,638.0 | $124.2 | $15,428.7 | $98.8 |
| 30 | $26,886.4 | $372.6 | $15,667.6 | $337.7 |
| 40 | $27,234.3 | $720.5 | $15,931.1 | $601.2 |
| % Increase in population aged ≥50 and ≥65 years | ||||
| +25 | $31,887.8 | $5374.0 | $18,407.4 | $3077.5 |
| +50 | $37,261.6 | $10,747.8 | $21,485.0 | $6155.1 |
| +100 | $48,009.4 | $21,495.6 | $27,640.0 | $12,310.1 |
aAbsolute dollar amount change (in millions) from the base case estimate
n.a. is not applicable, PHN is post-herpetic neuralgia